GLP-1
Life sciences companies across the globe are raking in investment dollars to advance drug programs.
It was a busy week for clinical trial announcements. Here’s a look.
In Phase III studies, Eli Lilly’s tirzepatide led to significant A1C and body weight reductions from baseline in adults with type 2 diabetes.
Data published in the New England Journal of Medicine shows the once-weekly dose of the glucagon-like peptide-1 (GLP-1) analog significantly reduced weight in patients over the course of 68 weeks.
Belgium-based Galapagos NV and Foster City, California-based Gilead Sciences halted the ISABELA Phase III clinical trial of ziritaxestat in idiopathic pulmonary fibrosis.
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.
Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look.
It’s been a busy day so far for biopharma news and updates. Read on for more.
It was an unusually busy week for clinical trial updates, largely because of the annual ASH meeting from Sunday December 5 through Wednesday December 9. There were also other meetings and the usual corporate updates.
Topline results from the Phase III SURPASS-1 trial show that a 40-week treatment with Eli Lilly’s tirzepatide led to significant reductions in A1c and body weight in adults with type 2 diabetes.
PRESS RELEASES